WallStSmart

Akso Health Group ADR (AHG)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Akso Health Group ADR generates 136% more annual revenue ($14.84M vs $6.28M). VUZI leads profitability with a 0.0% profit margin vs 0.0%. VUZI earns a higher WallStSmart Score of 26/100 (F).

AHG

Avoid

16

out of 100

Grade: F

Growth: 6.0Profit: 2.5Value: 6.0Quality: 7.5
Piotroski: 2/9Altman Z: 7.29

VUZI

Avoid

26

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: -4.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHGUndervalued (+19.4%)

Margin of Safety

+19.4%

Fair Value

$1.75

Current Price

$1.98

$0.23 discount

UndervaluedFair: $1.75Overvalued
VUZIUndervalued (+43.1%)

Margin of Safety

+43.1%

Fair Value

$4.34

Current Price

$3.11

$1.23 discount

UndervaluedFair: $4.34Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHG2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
7.2910/10

Safe zone — low bankruptcy risk

VUZI2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
76.3%10/10

Revenue surging 76.3% year-over-year

Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

AHG4 concerns · Avg: 3.8/10
Price/BookValuation
8.6x4/10

Trading at 8.6x book value

Revenue GrowthGrowth
0.9%4/10

0.9% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.76B3/10

Smaller company, higher risk/reward

VUZI4 concerns · Avg: 3.5/10
Price/BookValuation
10.4x4/10

Trading at 10.4x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$239.50M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : AHG

The strongest argument for AHG centers on Debt/Equity, Altman Z-Score.

Bull Case : VUZI

The strongest argument for VUZI centers on Revenue Growth, Debt/Equity. Revenue growth of 76.3% demonstrates continued momentum.

Bear Case : AHG

The primary concerns for AHG are Price/Book, Revenue Growth, EPS Growth.

Bear Case : VUZI

The primary concerns for VUZI are Price/Book, EPS Growth, Market Cap.

Key Dynamics to Monitor

AHG profiles as a value stock while VUZI is a hypergrowth play — different risk/reward profiles.

VUZI carries more volatility with a beta of 1.52 — expect wider price swings.

VUZI is growing revenue faster at 76.3% — sustainability is the question.

AHG generates stronger free cash flow (3M), providing more financial flexibility.

Bottom Line

VUZI scores higher overall (26/100 vs 16/100) and 76.3% revenue growth. AHG offers better value entry with a 19.4% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Akso Health Group ADR

HEALTHCARE · MEDICAL DISTRIBUTION · China

Akso Health Group ADR is a leading entity in the healthcare sector, focused on delivering innovative medical solutions and comprehensive patient care services. The company utilizes advanced health technologies to exploit burgeoning opportunities in telehealth and personalized medicine, supported by a strong emphasis on research and development. With a solid business model and a highly proficient workforce, Akso Health Group represents a compelling investment opportunity for institutional investors looking to capitalize on the dynamic changes within the healthcare industry.

Visit Website →

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?